Product Information
ERYTHROMYCIN 200 MG/5 ML SUSP is a generic product labeled by Wilshire Pharmaceuticals Inc., priced at $1.5203 per ML under NDC 52536013613. Its NADAC has been published 181 times since Sep 23, 2020.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/5mL
Manufacturer
Wilshire Pharmaceuticals Inc.NDC
52536013613
Classification
Generic
Dosage Form
GRANULE, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ERYTHROMYCIN ETHYLSUCCINATEApproval Type
New Drug (NDA)
FDA Application
NDA050207FDA Approved
Before 1982
TE Code
AB
On Market Since
9/28/2016
Pharmacological Classes
Price Statistics
The NADAC for ERYTHROMYCIN 200 MG/5 ML SUSP has been published 181 times since Sep 23, 2020, and over the history we have for it it has declined 41.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5203 per ML |
|---|---|
| All-time high | $2.5796 (Sep 15, 2021) |
| All-time low | $1.1184 (Nov 20, 2024) |
| 52-week high | $1.6022 |
| 52-week low | $1.4488 |
| Median price | $1.4781 |
| Average price | $1.7261 |
| Largest weekly change | -51.8% (Apr 17, 2024) |
| Weeks tracked | 181 |
| Tracking since | Sep 23, 2020 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 40% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Wilshire Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin Ethylsuccinate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYTHROMYCIN 200 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN 200 MG/5 ML SUSP, manufactured by Wilshire Pharmaceuticals Inc., is $1.5203 per ML (NDC 52536013613), effective Sep 30, 2026.
How has the price of ERYTHROMYCIN 200 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for ERYTHROMYCIN 200 MG/5 ML SUSP has declined 41.1%. It has been tracked across 181 weekly CMS publications since Sep 23, 2020.
What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN 200 MG/5 ML SUSP?
Since Sep 23, 2020, the NADAC for ERYTHROMYCIN 200 MG/5 ML SUSP has ranged from a low of $1.1184 (Nov 20, 2024) to a high of $2.5796 (Sep 15, 2021), with a median of $1.4781 per ML.
Are there cheaper alternatives to ERYTHROMYCIN 200 MG/5 ML SUSP?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ERYTHROMYCIN 200 MG/5 ML SUSP, is $0.9123 per ML — about 40% below ERYTHROMYCIN 200 MG/5 ML SUSP.
Who manufactures ERYTHROMYCIN 200 MG/5 ML SUSP?
ERYTHROMYCIN 200 MG/5 ML SUSP (NDC 52536013613) is labeled by Wilshire Pharmaceuticals Inc., and CMS classifies it as a generic product.